GILD pulls down IBB

Gild add a great quarter IMO. Gilead posted strong fourth-quarter results with both earnings and revenues beating our expectations. We are nevertheless concerned about additional pricing measures to reduce HCV spending in the form of rebates and discounts which could lead to a slowdown in Harvoni sales in 2015. The company’s 2015 revenue guidance came in below our expectations. The stock was down in early trading. We note that several companies including AbbVie Inc. (ABBV) have launched their HCV treatments in the market. So with that IBB went down to $305.11. I bought a few IBB Mar 20, 2015 Calls at $8.50 and sold at $9.30 made a little money. Missing buying more at the bottom. I still have 42 IBB Feb 20, 2015 Calls at $322.50. Hoping for a $8 move up soon. IBB closed at $312.55 with a range of $305.11 to $314.68. May buy some GILD Calls if it goes down to $95. If IBB goes down to $305 again will buy 10-20 Mar 20 $315 Calls. Good luck in this rigged casino.